RVMD - Revolution Medicines, Inc.
Revolution Medicines Inc. (NASDAQ:RVMD) began treating patients in its global Phase 3 clinical study, RASolve 308, to evaluate a combination treatment for metastatic lung cancer.
REDWOOD CITY, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that it has begun treating patients in RASolve 308, a global Phase 3 clinical trial evaluating zoldonrasib, an investigational, RAS(ON) G12D-selective inhibitor, in combination with standard of care pembrolizumab plus chemotherapy as a first-line treatment in adult patients with metastatic RAS G12D non-squamous non-small cell lung cancer (NSCLC).
SteelPeak Wealth LLC acquired a new stake in Revolution Medicines, Inc. (NASDAQ: RVMD) in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 7,403 shares of the company's stock, valued at approximately $1,520,000. Other large investors also recently made changes to
First Citizens Bank and Trust Co. purchased a new position in shares of Revolution Medicines, Inc. (NASDAQ: RVMD) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 3,373 shares of the company's stock, valued at approximately $692,000. Other hedge
Revolution Medicines Inc. (NASDAQ:RVMD) has significant growth opportunities beyond pancreatic cancer, according to William Blair, which initiated coverage of the biotechnology company with an Outperform rating and a $226 price forecast.
Assenagon Asset Management S.A. grew its holdings in shares of Revolution Medicines, Inc. (NASDAQ: RVMD) by 987.9% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,181,185 shares of the company's stock after purchasing an additional 1,980,699 shares during
Recommendation based on results from Phase 3 RASolute 302 trial, which demonstrated a 60% reduction in risk of death compared with chemotherapy in the overall study population with statistically significant and clinically meaningful improvements across all primary and key secondary endpoints, regardless of tumor RAS mutation status Positive CHMP opinion follows an expedited phased review of RASONQUE under the EMA's Cancer Medicines Pathfinder project based on its potential to address a high unmet medical need REDWOOD CITY, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion of RASONQUE (daraxonrasib) once-daily oral tablets as a monotherapy indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy.
Wall Street kicked off the first full week of Q4 2026 with a flurry of bold analyst moves, including a sweeping Microsoft upgrade and a brutal Align Technology target slash. Find out which names got upgraded, downgraded, or freshly initiated before the opening bell.
REDWOOD CITY, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that it has begun treating patients in RASolute 309, a global, randomized Phase 3 clinical trial evaluating the combination of RASONQUE (daraxonrasib), a RAS(ON) multi-selective inhibitor, and zoldonrasib, an investigational RAS(ON) G12D-selective inhibitor, as a first-line treatment in adult patients with metastatic RAS G12D pancreatic adenocarcinoma (PDAC).
Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) Director Elizabeth Anderson sold 10,143 shares of the firm's stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $193.04, for a total transaction of $1,958,004.72. Following the completion of the transaction, the director directly owned 4,333 shares
Revolution Medicines has just received good news around a drug meant to treat pancreatic cancer. While the company has multiple drugs in development, buying Revolution Medicines is still basically like putting all of your eggs in one basket.
Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) insider Alan Sandler sold 341 shares of Revolution Medicines stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $199.24, for a total value of $67,940.84. Following the completion of the transaction, the insider directly owned 52,868 shares of the
Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) CFO Jack Anders sold 4,053 shares of the company's stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $199.24, for a total transaction of $807,519.72. Following the completion of the transaction, the chief financial officer owned 119,216
Axsome Therapeutics is generating rapid revenue growth through its expanding portfolio of commercialized central nervous system treatments. Revolution Medicines is advancing a high-potential pipeline of RAS(ON) inhibitors aimed at treating some of the most difficult cancers.
Engineers Gate Manager LP increased its stake in shares of Revolution Medicines, Inc. (NASDAQ: RVMD) by 144.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,380 shares of the company's stock after purchasing an additional 4,356 shares during the quarter.
Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) insider Stephen Kelsey sold 92,531 shares of the stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $202.36, for a total transaction of $18,724,573.16. Following the transaction, the insider directly owned 291,876 shares of the company's stock, valued at
Revolution Medicines validated its approach to treating certain cancers with a recent regulatory approval. The company's new medicine might become the top-prescribed treatment in its indication.
Concurrent Investment Advisors LLC bought a new stake in Revolution Medicines, Inc. (NASDAQ: RVMD) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 2,534 shares of the company's stock, valued at approximately $475,000. Several other large investors have also modified their
REDWOOD CITY, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to RASONQUE (daraxonrasib), the company's RAS(ON) multi-selective inhibitor, for treatment-naïve metastatic pancreatic adenocarcinoma (PDAC) in combination with gemcitabine and nab-paclitaxel (GnP), a multiagent chemotherapy regimen widely used in treating patients with PDAC. RASONQUE was recently approved by the U.S. FDA for the treatment of adult patients with metastatic PDAC who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) Director Lorence Kim sold 17,090 shares of the firm's stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $209.82, for a total transaction of $3,585,823.80. The sale was disclosed in a filing with the SEC, which is accessible through